Version 2 2024-06-04, 07:46Version 2 2024-06-04, 07:46
Version 1 2021-10-04, 22:22Version 1 2021-10-04, 22:22
journal contribution
posted on 2024-06-04, 07:46authored byYM Arabi, AC Gordon, LPG Derde, AD Nichol, S Murthy, FA Beidh, D Annane, LA Swaidan, A Beane, R Beasley, LR Berry, Z Bhimani, MJM Bonten, CA Bradbury, FM Brunkhorst, M Buxton, A Buzgau, A Cheng, M De Jong, MA Detry, EJ Duffy, LJ Estcourt, M Fitzgerald, R Fowler, TD Girard, EC Goligher, H Goossens, R Haniffa, AM Higgins, TE Hills, CM Horvat, DT Huang, AJ King, F Lamontagne, PR Lawler, R Lewis, K Linstrum, E Litton, E Lorenzi, S Malakouti, DF McAuley, A McGlothlin, S Mcguinness, BJ McVerry, SK Montgomery, SC Morpeth, PR Mouncey, K Orr, R Parke, JC Parker, AE Patanwala, KM Rowan, MS Santos, CT Saunders, CW Seymour, M Shankar-Hari, SYC Tong, AF Turgeon, AM Turner, FL Van de Veerdonk, R Zarychanski, C Green, S Berry, JC Marshall, C McArthur, DC Angus, SA Webb, Neil OrfordNeil Orford
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial